Engineered Small Extracellular Vesicles Targeting Tumor-Associated Endothelial Cells to Effectively Remodel the...

Area of Science:

• Neuro-oncology
• Nanomedicine
• Immunotherapy

Background:

• Glioblastoma treatment is hindered by the blood-brain barrier (BBB), limiting drug delivery.
• Targeting glioma-associated vascular endothelial cells (VECs) is a key strategy for effective glioblastoma therapy.

Purpose of the Study:

• To develop a novel drug delivery platform for glioblastoma targeting CD93-expressing VECs.
• To evaluate the efficacy of modified small extracellular vesicles (sEVs) for delivering therapeutic agents, including chemotherapy and immunotherapy.

Main Methods:

• Engineered small extracellular vesicles (sEVs) by modifying them with insulin-like growth factor-binding protein 7 (IGFBP7), a CD93 ligand.
• Loaded sEVs with temozolomide (TMZ) and stimulator of interferon genes (STING) agonists for targeted delivery.
• Assessed therapeutic efficacy in glioblastoma models, evaluating tumor growth inhibition and immune response modulation.

Main Results:

• IGFBP7-modified sEVs efficiently delivered therapeutic agents to glioma-associated VECs.
• Systemic administration of IGFBP7-sEVs loaded with TMZ showed significant tumor growth inhibition.
• STING agonist-loaded IGFBP7-sEVs remodeled the glioma microenvironment, enhanced antigen presentation, and boosted anti-tumor immunity.

Conclusions:

• IGFBP7-modified sEVs represent a versatile platform for targeted glioblastoma therapy.
• This approach enables efficient delivery of various agents, particularly immunomodulators, to glioma VECs.
• The strategy offers a promising new avenue for glioblastoma treatment by overcoming BBB limitations and enhancing anti-tumor immunity.